<div id="readability-page-1"><p>In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Gain Therapeutics, with a price target of <span id="expert-recommendation-target">$6.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Pachaiyappan covers the Healthcare sector, focusing on stocks such as Cingulate Inc, CervoMed, and PolyPid. According to TipRanks, Pachaiyappan has an average return of <span>-10.0%</span> and a 34.31% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gain Therapeutics with a $6.80 average price target.</p></div>

GANX

<p>Roth MKM's Boobalan Pachaiyappan reiterated a Buy rating for Gain Therapeutics with a $6.00 price target. Despite Pachaiyappan's average return of -10.0% and a 34.31% success rate, the general analyst consensus is a Strong Buy with a $6.80 average price target for Gain Therapeutics.</p>

Roth MKM Sticks to Its Buy Rating for Gain Therapeutics (GANX)